- Home
- Plasma
- Plasma Protein Therapies
- Safety & Quality
- Standards Programs
- Regulatory Policy
- Pathogen Safety
- Donor History Questionnaire
- National Donor Deferral Registry
- North America Programs
- European Programs
- Meetings & Events
- IPAW
- About Us
- Topics
- Access to Care
- Regulatory & Quality Policy
- Communication & Advocacy
- Free Trade
- Plasma
- Regions
Sitemap
- Mainmenu
- Plasma Products Database Menu
- Media and Information Menu
- Advocacy Menu
- Bottommenu
- Hidden Menu
- Uncategorized
- Plasma Protein Therapies
- Quality and Standards
- Meetings and Events
- PPTA Business Forum
- About Us
- Regulatory Policy
- Current Members
- Plasma Products Database
- Albumin
- Alzheimer's
- The capacity of albumin to bind to beta-amyloid
- Human Albumin Grifols 5% in plasmapheresis: a new therapy involving beta-amyloid mobilisation in Alzheimer's disease
- Amyloid-targeted therapeutics in Alzheimer's disease: use of human albumin in plasma exchange as a novel approach for Abeta mobilization.
- Blood-based biomarkers of Alzheimer's disease: challenging but feasible.
- The Cu(II)/Abeta/human serum albumin model of control mechanism for copper-related amyloid neurotoxicity.
- Neuroimaging in Alzheimer's disease: findings in plasmapheresis with albumin
- [Therapeutic plasmapheresis and experience in Alzheimer's disease].
- ARDS/ALI
- A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute lung injury.
- Fluid balance and colloid osmotic pressure in acute respiratory failure: emerging clinical evidence.
- Albumin and furosemide therapy in hypoproteinemic patients with acute lung injury.
- Understanding and managing fluid balance in patients with acute lung injury.
- Twenty-five percent albumin prevents lung injury following shock/resuscitation.
- Immediate effects of albumin infusion in ill premature neonates.
- Ascites
- Progress in treatment of massive ascites and hepatorenal syndrome.
- Management of ascites.
- Is the use of albumin of value in cirrhosis? The case not so in favour, or is there an alternative?
- Combined furosemide and human albumin treatment for diuretic-resistant edema.
- Albumin improves the response to diuretics in patients with cirrhosis and ascites.
- Burns
- Burn patient characteristics and outcomes following resuscitation with albumin.
- Reversal of the effect of albumin on gut barrier function in burn by the inhibition of inducible isoform of nitric oxide synthase.
- Impact of burn size and initial serum albumin level on acute renal failure occurring in major burn.
- Cardiac Surgery
- Ischemia-modified albumin in acute aortic dissection.
- Ischemia-modified albumin is a highly sensitive serum marker of transient myocardial ischemia induced by coronary vasospasm.
- Comparison of Hemodynamic Changes After Acute Normovolemic Hemodilution Using Ringer's Lactate Versus 5% Albumin in Patients on beta-Blockers Undergoing Coronary Artery Bypass Surgery.
- Cardiac response is greater for colloid than saline fluid loading after cardiac or vascular surgery.
- Intra- and extravascular volume status in patients undergoing mitral valve replacement: crystalloid vs. colloid priming of cardiopulmonary bypass.
- Improved outcomes during cardiac surgery: a multifactorial enhancement of cardiopulmonary bypass techniques.
- Increased complications and prolonged hospital stay in elderly cardiac surgical patients with low serum albumin.
- The epidemiology of hemorrhage related to cardiothoracic operations.
- No evidence of excess mortality in patients receiving human albumin: a meta-analysis of randomized controlled trials
- Serum albumin and risk of myocardial infarction and all-cause mortality in the Framingham Offspring Study.
- Priming of cardiopulmonary bypass with human albumin or Ringer lactate: effect on colloid osmotic pressure and extravascular lung water.
- Volume expansion with albumin decreases mortality after coronary artery bypass graft surgery.
- Oxygen transport and myocardial function after the administration of albumin 5%, hydroxyethylstarch 6% and succinylated gelatine 4% to rabbits.
- Does priming implementation with low-dose albumin reduce postoperative bleeding following cardiopulmonary bypass?
- Albumin versus crystalloid for pump priming in cardiac surgery: Meta-analysis of controlled trials.
- Hydroxyethyl Starch as a Priming Solution for Cardiopulmonary Bypass Impairs Hemostasis After Cardiac Surgery.
- Distribution of normal saline and 5% albumin infusions in cardiac surgical patients.
- Blood loss in infants and children for open heart operations: albumin 5% versus fresh-frozen plasma in the prime.
- Albumin versus hydroxyethyl starch in cardiopulmonary bypass surgery: a meta-analysis of postoperative bleeding.
- A prospective randomized study of hydroxyethyl starch, albumin, and lactated Ringer's solution as priming fluid for cardiopulmonary bypass.
- Hepatology
- Albumin: Pathophysiologic basis of its role in the treatment of cirrhosis and its complications.
- Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites: molecular mechanisms.
- Albumin infusion in patients undergoing large-volume paracentesis: A meta-analysis of randomized trials.
- Diagnosis and therapy of ascites in liver cirrhosis.
- Role of artificial liver support in hepatic encephalopathy.
- Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis.
- Terlipressin and Albumin in Patients with Cirrhosis and Type I Hepatorenal Syndrome.
- [Comparative study of hospital costs associated with human albumin 20% (Vialebex((R)) 20%) or polygeline as a fluid resuscitation strategy for cirrhotic ascites.]
- Prevention and treatment of infections in patients with cirrhosis.
- Diagnosis and treatment of acute renal failure in patients with cirrhosis.
- [Renal dysfunction after spontaneous bacterial peritonitis in cirrhosis: incidence and risk factors.
- New treatments of hepatorenal syndrome.
- Long-term albumin infusion improves survival in patients with cirrhosis and ascites: An unblinded randomized trial.
- The management of severe alcoholic liver disease and variceal bleeding in the intensive care unit.
- Treatment of hepatorenal syndrome as defined by the international ascites club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study.
- Effects of artificial liver support system on patients with acute or chronic liver failure.
- A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis.
- Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis.
- Chronic albumin infusions to achieve diuresis in patients with ascites who are not candidates for transjugular intrahepatic portosystemic shunt (TIPS).
- Long-term clinical outcome of large volume paracentesis with intravenous albumin in patients with spontaneous bacterial peritonitis: A randomized prospective study.
- Albumin: Biochemical properties and therapeutic potential.
- Pathophysiological basis of therapy of raised intracranial pressure in acute liver failure.
- [Advances in Therapy for Ascites and Hepatorenal Syndrome.]
- The use of albumin in patients with decompensated cirrhosis: the case in favor.
- Hepatorenal syndrome: a dreaded complication of end-stage liver disease.
- Worsening of hepatic dysfunction as a consequence of repeated hydroxyethylstarch infusions.
- The rational use of albumin in patients with cirrhosis and ascites. A Delphi study for the attainment of a consensus on prescribing standards.
- Review article: albumin for circulatory support in patients with cirrhosis.
- Review article: albumin in the treatment of liver diseases-new features of a classical treatment.
- Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion.
- Pruritus in chronic liver disease: mechanisms and treatment.
- Prometheus((R)) - a new extracorporeal system for the treatment of liver failure( small star, filled).
- Plasma volume expansion by albumin in cirrhosis. Relation to blood volume distribution, arterial compliance and severity of disease.
- Is the use of albumin of value in the treatment of ascites in cirrhosis? The case in favour.
- Influence of long-term administration of serum albumin on the prognosis of liver cirrhosis in man.
- Chronic liver and renal diseases differently affect structure of human serum albumin.
- Hepatorenal syndrome.
- Extracorporeal liver support: waiting for the deciding vote.
- Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin but not colloid.
- Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study.
- Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.
- Albumin versus Crystalloid Therapy in the Management of Hepatorenal Syndrome: A Model for using Meta Analysis in Cost Effectiveness Studies and the Design of Clinical Trials.
- Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial.
- Albumin dialysis: effective removal of copper in a patient with fulminant Wilson disease and successful bridging to liver transplantation: a new possibility for the elimination of protein-bound toxins.
- Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study.
- Use of albumin in the management of patients with decompensated cirrhosis. An independent verdict.
- Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial.
- Update on ascites and hepatorenal syndrome.
- Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and SBP.
- Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites.
- Spontaneous Bacterial Peritonitis.
- Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites.
- Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis.
- Plasma volume expansion by albumin in cirrhosis. Relation to blood volume distribution, arterial compliance and severity of disease.
- Hypo-albuminaemia
- A Simple Novel Model to Predict Hospital Mortality, Surgical Site Infection, and Pneumonia in Elderly Patients Undergoing Operation.
- Serum albumin level as a predictor of outcome in traumatic brain injury: potential for treatment.
- Hypoalbuminemia is a predictor of delayed postoperative bowel function and poor surgical outcomes in right-sided colon cancer patients.
- Albumin administration improves organ function in critically ill hypoalbuminemic patients: A prospective, randomized, controlled, pilot study
- Correction of the anion gap for albumin in order to detect occult tissue anions in shock.
- Admission serum albumin is predicitve of outcome in critically ill trauma patients.
- Cholesterol and serum albumin levels as predictors of cross infection, death, and length of hospital stay.
- Serum albumin level on admission as a predictor of death, length of stay, and readmission.
- Linkage of hypoalbuminemia, inflammation, and oxidative stress in patients receiving maintenance hemodialysis therapy.
- Protein malnutrition and hypoalbuminemia as predictors of vascular events and mortality in ESRD.
- Role of soluble receptors for tumor necrosis factor alpha in the development of hypoalbuminemia in hemodialysis patients.
- Hypoalbuminemia in acute illness: is there a rationale for intervention?: a meta-analysis of cohort studies and controlled trials.
- Hypoalbuminemia as a cause of pleural effusions.
- Hypoalbuminemia accelerates erythrocyte membrane lipid peroxidation in chronic hemodialysis patients
- Effect on platelet function of hypoalbuminemia in peritoneal dialysis.
- [Hypoalbuminemia and invalidating edema in an elderly subject: treatment with parenteral albumin infusion]
- Use of albumin in the intensive care unit.
- Hypo-volemia
- Plasma volume expansion of 5% albumin, 4% gelatin, 6% HES 130/0.4, and normal saline under increased microvascular permeability in the rat.
- Volume expansion of albumin, gelatin, hydroxyethyl starch, saline and erythrocytes after haemorrhage in the rat.
- Debate: Albumin administration should not be avoided.
- Influences on physicians' choices of intravenous colloids.
- Human albumin and colloid fluid replacement: their use in general surgery.
- Early albumin infusion improves global and local hemodynamics and reduces inflammatory response in hemorrhagic shock.
- Albumin and artificial colloids in fluid management: where does the clinical evidence of their utility stand?
- A comparison of 4.5% human albumin solution and Haemaccel in neonates undergoing major surgery.
- Pulmonary edema during volume infusion.
- Albumin in critical care: SAFE, but worth its salt?
- Kidney/Liver Transplant
- Albumin Dialysis
- Extracorporeal liver support with multipass albumin dialysis or plasmapheresis and filtering systems in acute liver failure.
- Extracorporeal liver support-albumin dialysis with the Molecular Adsorbent Recirculating System (MARS).
- Management of sepsis during Mars treatment in acute on chronic liver failure.
- Liver support systems today.
- Extracorporeal albumin dialysis.
- Molecular adsorbent recirculating system (Mars) in patients with primary nonfunction and other causes of graft dysfunction after liver transplantation in the era of extended criteria donor organs.
- Use of the molecular adsorbents recirculating system as a treatment for acute decompensated wilson disease.
- Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis.
- Albumin-binding function is reduced in patients with decompensated cirrhosis and correlates inversely with severity of liver disease assessed by model for end-stage liver disease.
- Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure.
- Bridging to transplantation in acute liver failure in a 7-month-old infant.
- Molecular adsorbent recirculating system in patients with early allograft dysfunction after liver transplantation: A pilot study.
- Albumin regeneration in liver support-comparison of different methods.
- Removal selectivity of Prometheus: a new extracorporeal liver support device.
- Prometheus versus molecular adsorbents recirculating system: comparison of efficiency in two different liver detoxification devices.
- In vitro comparison of the molecular adsorbent recirculation system (MARS) and single-pass albumin dialysis (SPAD).
- Fulminant hepatic failure bridged to liver transplantation with a molecular adsorbent recirculating system: a single-center experience.
- A pilot study of using pure albumin as a dialysate in the treatment of liver failure
- Successful treatment of an adult with Amanita Phalloides - induced fulminant liver failure with molecular adsorbent recirculating system (MARS).
- The effect of albumin dialysis on cytokine levels in acute liver failure and need for liver transplantation.
- Therapy of intractable pruritus with Mars.
- [Extracorporeal Blood Purification in Severe Liver Failure with the Albumin Dialysis MARS(R) - Impact on Relevant Intensive Care Parameters.]
- [Molecular adsorption in liver failure
- Emerging indications for albumin dialysis.
- MARS treatment for a patient presenting with acquired hepatic glutamine synthetase deficiency after orthotopic liver transplantation.
- Albumin dialysis in cirrhosis with superimposed acute liver injury: possible impact of albumin dialysis on hospitalization costs.
- Characterization of treatment dose delivered by albumin dialysis in the treatment of acute renal failure associated with severe hepatic dysfunction.
- Role of the molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure.
- MARS--does it stand the test of time?
- Review article: the Molecular Adsorbents Recirculating System (MARS) in liver failure.
- Predicting the decrease of conjugated bilirubin with extracorporeal albumin dialysis MARS using the predialysis molar ratio of conjugated bilirubin to albumin.
- Liver support by extracorporeal blood purification: a clinical observation.
- Liver albumin dialysis--application in acetaminophen poisoning
- Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial.
- Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure.
- Hypoglycemia in nondiabetic patients undergoing albumin dialysis by molecular adsorbent recirculating system.
- Application of MARS artificial liver support as bridging therapy before split liver retransplantation in a 15-month-old child.
- Albumin dialysis and Molecular Adsorbents Recirculating System (MARS) for acute Wilson's disease.
- Case Report of the First Severe Acute Respiratory Syndrome Patient in China: Successful Application of Extracorporeal Liver Support MARS Therapy in Multiorgan Failure Possibly Induced by Severe Acute Respiratory Syndrome.
- Nephrotic Syndrome
- Elderly patients with acute kidney injury (AKI): Clinical features and risk factors for mortality.
- Acute liver failure due to leptospirosis successfully treated with MARS (molecular adsorbent recirculating system) dialysis.
- Comparison of the diuretic effect of furosemide mixed with human albumin or fresh frozen plasma for patients with hypoalbuminemia in the intensive care unit.
- Hypoalbuminaemia enhances the renal vasoconstrictor effect of lysophosphatidylcholine.
- Does albumin preinfusion potentiate diuretic action of furosemide in patients with nephrotic syndrom
- Does albumin and furosemide therapy affect plasma volume in nephrotic children?
- Coadministration of albumin and furosemide in patients with the nephrotic syndrome.
- Increased risk for cardiovascular mortality among malnourished end-stage renal disease patients.
- Neurology/Stroke
- Albumin attenuates DNA damage in primary-cultured neurons.
- Serum albumin at admission for prediction of functional outcome in ischaemic stroke patients.
- Albumin therapy in acute stroke patients.
- Oxidative and nitrosative stress in acute ischaemic stroke.
- Hypoalbuminemia in acute ischemic stroke patients: frequency and correlates.
- Experimental treatments for acute ischaemic stroke.
- Ischemia-Modified Albumin in Acute Stroke.
- The ALIAS (ALbumin In Acute Stroke) Phase III randomized multicentre clinical trial: design and progress report.
- The ALIAS Pilot Trial. A Dose-Escalation and Safety Study of Albumin Therapy for Acute Ischemic Stroke--I: Physiological Responses and Safety Results.
- Serum albumin level and nosocomial pneumonia in stroke patients.
- Serum albumin and self-reported prevalence of stroke: a population-based, cross-sectional study.
- Albumin protects cultured cerebellar granule neurons against zinc neurotoxicity.
- Intraventricular albumin: an optional agent in experimental post-traumatic brain edema.
- Albumin Treatment Reduces Neurological Deficit and Protects Blood-Brain Barrier Integrity After Acute Intracortical Hematoma in the Rat.
- Transient forebrain ischemia increases the blood-brain barrier permeability for albumin in stroke-prone spontaneously hypertensive rats.
- Systemic fatty acid responses to transient focal cerebral ischemia: influence of neuroprotectant therapy with human albumin.
- Serum Albumin Level as a Predictor of Ischemic Stroke Outcome.
- Potential Role of Neuroprotective Agents in the Treatment of Patients with Acute Ischemic Stroke.
- Human Serum Albumin and its N-Terminal Tetrapeptide (DAHK) Block Oxidant-Induced Neuronal Death.
- Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window.
- Effect of human albumin administration on clinical outcome and hospital cost in patients with subarachnoid hemorrhage.
- Bedside Monitoring of Circulating Blood Volume After Subarachnoid Hemorrhage.
- Effect of 5% albumin solution on sodium balance and blood volume after subarachnoid hemorrhage.
- Diffusion-weighted magnetic resonance imaging confirms marked neuroprotective efficacy of albumin therapy in focal cerebral ischemia.
- Albumin use in neurosurgical critical care.
- Albumin therapy of transient focal cerebral ischemia: in vivo analysis of dynamic microvascular responses.
- Albumin promotes neuronal survival by increasing the synthesis and release of glutamate.
- Adventures in the Pathophysiology of Brain Ischemia: Penumbra, Gene Expression, Neuroprotection: The 2002 Thomas Willis Lecture.
- Other Indications
- Safety of Plasma Volume Expanders.
- Albumin usage in clinical medicine: tradition or therapeutic?
- Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus.
- Small-volume resuscitation with hyperoncotic albumin: a systematic review of randomized clinical trials.
- A comparison of albumin-bolus therapy versus normal saline-bolus therapy for hypotension in neonates
- Evaluation of the albumin cobalt binding (ACB) assay for measurement of ischaemia-modified albumin (IMA) on the Beckman Coulter LX-20.
- Use of albumin in three French university hospitals: is prescription monitoring still useful in 2004?
- Contrasting Effects of Colloid and Crystalloid Resuscitation Fluids on Cardiac Vascular Permeability
- Albumin therapy in clinical practice.
- The effect of albumin priming solution on platelet activation during experimental long-term perfusion.
- Serum albumin decreases transendothelial permeability to macromolecules.
- Review article: albumin as a drug-biological effects of albumin unrelated to oncotic pressure.
- Practical aspects of the ligand-binding and enzymatic properties of human serum albumin.
- Pharmacoeconomic comparison of an albumin-furosemide complex versus sequential therapy for renal insufficiency.
- Management of a severe carbamazepine overdose using albumin-enhanced continuous venovenous hemodialysis.
- Small volume albumin administration protects against hemorrhagic shock-induced bone marrow dysfunction.
- Intrauterine treatment on non-immune hydrops fetalis.
- Inhibition of microvascular endothelial apoptosis in tissue explants by serum albumin.
- Human neutrophil activation and increased adhesion by various resuscitation fluids.
- Concurrent administration of albumin with total parenteral nutrition in sick newborn infants.
- Antioxidant activity of albumin-bound bilirubin.
- Albumin prevents erythrocyte crenation in patients undergoing extracorporeal circulation.
- Albumin influences total plasma antioxidant capacity favorably in patients with acute lung injury.
- A paradigm for consensus. The University Hospital Consortium guidelines for the use of albumin, nonprotein colloid, and crystalloid solutions.
- Albumin is a major serum survival factor for renal tubular cells and macrophages through scavenging of ROS.
- Serum albumin (oncotic pressure) correlates with enteral feeding tolerance in the pediatric surgical patient.
- Concentrated albumin infusion as an aid to postoperative recovery after pelvic exenteration.
- Albumin at the start of peritoneal dialysis predicts the development of peritonitis.
- Albumin resuscitation increases cardiomyocyte contractility and decreases nitric oxide synthase II expression in rat endotoxemia.
- Factors that affect albumin concentration in dialysis patients and their relationship to vascular disease.
- Evaluation of the appropriate use of albumin in adult and pediatric patients.
- Effect of albumin supplementation during parenteral nutrition on hospital morbidity.
- OHSS
- Intravenous albumin prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized and controlled study.
- Intra-venous albumin for preventing severe ovarian hyperstimulation syndrome.
- Intravenous albumin for preventing severe ovarian hyperstimulation syndrome: a Cochrane review.
- Comparison of coasting and intravenous albumin in the prevention of ovarian hyperstimulation syndrom
- An ounce of prevention: outpatient management of the ovarian hyperstimulation syndrome.
- Decreased incidence of severe ovarian hyperstimulation syndrome in high risk in-vitro fertilization patients receiving intravenous albumin: a prospective study.
- Plasma Exchange
- Safety Profile
- Conflicting clinical trial data: a lesson from albumin.
- Inactivation of viral and prion pathogens by gamma-irradiation under conditions that maintain the integrity of human albumin.
- Safety of human albumin-serious adverse events reported worldwide in 1998-2000( dagger ).
- Safety of human albumin based on spontaneously reported serious adverse events.
- Sepsis
- Relative Survival Benefit and Morbidity with Fluids in Severe Sepsis-A Network Meta-Analysis of Alternative Therapies.
- Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis.
- The role of albumin as a resuscitation fluid for patients with sepsis: a systematic review and meta-analysis.
- Albumin administration improves survival in severe sepsis and septic shock – the ALBIOS study
- A comparison of albumin and saline for fluid resuscitation in the intensive care unit.
- Administration of albumin to patients with sepsis syndrome: a possible beneficial role in plasma thiol repletion.
- Systematic Review
- Malaria
- Pre-transfusion management of children with severe malarial anaemia: a randomised controlled trial of intravascular volume expansion.
- Randomized Trial of Volume Expansion with Albumin or Saline in Children with SevereMalaria: Preliminary Evidence of Albumin Benefit
- Volume Expansion with Albumin Compared to Gelofusine in Children with Severe Malaria: Results of a Controlled Trial.
- Immunoglobulin
- Cardiology
- A case of immunoglobulin G4-related constrictive pericarditis.
- Junctional Bradycardia as Early Sign of Digoxin Toxicity in a Premature Infant with Congestive Heart Failure due to a Left to Right Shunt.
- Pregnancy in lupus.
- Fetal congenital complete heart block: prophylaxis with intravenous gammaglobulin and treatment with dexamethasone.
- Treatment of neonatal lupus: case report and review of the literature.
- Dermatology
- Response of livedoid vasculitis to intravenous immunoglobulin.
- High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Chinese patients: a retrospective study of 82 cases.
- Treatment of toxic epidermal necrolysis (TEN) with low dose intravenous immunoglobulin in child.
- Pulsed intravenous immunoglobulin therapy in livedoid vasculitis: an open trial evaluating 9 consecutive patients.
- Update on the management of antibiotic allergy.
- Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study.
- Intravenous immunoglobulin use in patients with toxic epidermal necrolysis and stevens-johnson syndrome.
- Use of intravenous immunoglobulin in the treatment of severe cutaneous drug reactions in patients with AIDS.
- Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding.
- Successful intravenous human immunoglobulin treatment of drug-induced Stevens-Johnson syndrome in a dog.
- Toxic epidermal necrolysis and intravenous immunoglobulin: a review.
- Intravenous immunoglobulin prophylaxis for recurrent Stevens-Johnson syndrome.
- [Treatment of toxic epidermal necrolyis Experience with 9 patients with consideration of intravenous immunoglobulin.]
- Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: Our current understanding.
- Use of intravenous immunoglobulin in children with stevens-johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature.
- Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: An open uncontrolled study.
- High-dose intravenous immunoglobulins in the treatment of toxic epidermal necrolysis: an Asian series.
- Intravenous immunoglobulin for treatment of toxic epidermal necrolysis.
- Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience.
- Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases.
- Treatment of toxic epidermal necrolysis in AIDS with intravenous immunoglobulins.
- High-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefits.
- Nevirapine-induced toxic epidermal necrolysis and toxic hepatitis treated successfully with a combination of intravenous immunoglobulins and N-acetylcysteine.
- Fatal toxic epidermal necrolysis in autoimmune polyglandular syndrome type I.
- Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis.
- Acetaminophen-induced toxic epidermal necrolysis in a child.
- Treatment of toxic epidermal necrolysis with intravenous immunoglobulin.
- Toxic epidermal necrolysis: does immunoglobulin make a difference?
- High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis.
- Improvement of toxic epidermal necrolysis after the early administration of a single high dose of intravenous immunoglobulin.
- Intravenous immunoglobulins in the treatment of severe drug eruptions.
- ESID Registry
- Clinical Features, Non-Infectious Manifestations and Survival Analysis of 161 Children with Primary Immunodeficiency in Mexico: A Single Center Experience Over two Decades.
- The ESID Online Database network.
- Primary immunodeficiency registries
- Neuroendocrine carcinoma associated with X-linked hyper-immunoglobulin M syndrome: report of four cases and review of the literature.
- The European internet-based patient and research database for primary immunodeficiencies: results 2004-06.
- The European internet-based patient and research database for primary immunodeficiencies: results 2006-2008.
- Genetic and demographic features of X-linked agammaglobulinemia in Eastern and Central Europe: a cohort study.
- The French national registry of primary immunodeficiency diseases
- X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options.
- Invasive mold infections in chronic granulomatous disease: a 25-year retrospective survey.
- Epidemiology and outcome of invasive fungal diseases in patients with chronic granulomatous disease: a multicenter study in France.
- Morbidity and mortality from ataxia-telangiectasia are associated with ATM genotype.
- Immunoglobulin deficiencies: the B-lymphocyte side of DiGeorge Syndrome.
- The prevalences [correction] and patient characteristics of primary immunodeficiency diseases in Turkey--two centers study.
- Characteristics and outcome of early-onset, severe forms of Wiskott-Aldrich syndrome.
- Therapeutic management of primary immunodeficiency in older patients.
- The German National Registry for Primary Immunodeficiencies (PI).
- Guidelines
- [Use of intravenous polyclonal immunoglobulins in autoimmune and inflammatory disorders.]
- How intravenous immunoglobulin is used in clinical practice: audits of two Sydney teaching hospitals.
- Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology.
- Intravenous Immunoglobulin: Striving for Appropriate Use.
- Core SPC IVIG EMEA
- Guidelines Europe
- Guidelines US
- Hematology
- Treatment of platelet alloimmunization with intravenous immunoglobulin. Two case reports and review of the literature.
- Successful anti-CD20 monoclonal antibody treatment of severe autoimmune hemolytic anemia due to warm reactive IgM autoantibody in a child with common variable immunodeficiency.
- The efficacy of different dose intravenous immunoglobulin in treating acute idiopathic thrombocytopenic purpura: a meta-analysis of 13 randomized controlled trials.
- Follow up of children after antenatal treatment for alloimmune thrombocytopenia.
- Remission of a lymphoproliferative disorder occurring after second BMT from an unrelated donor in a 5-year-old boy with severe aplastic anemia.
- Case report: exacerbation of hemolytic anemia requiring multiple incompatible RBC transfusions.
- Intravenous immunoglobulins induce potentially synergistic immunomodulations in autoimmune disorders.
- The immunologic profile of infants born after maternal immunoglobulin treatment and intrauterine platelet transfusions for fetal/neonatal alloimmune thrombocytopenia.
- Treatment of platelet alloimmunization with intravenous immunoglobulin in a child with aplastic anemia.
- Successful management of severe chronic autoimmune hemolytic anemia with low dose cyclosporine and prednisone in an infant.
- Treatment of immune-mediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: A retrospective review of 40 patients.
- [Three special cases of pregnancy outcome to reflect about]
- Successful bone marrow transplantation for severe aplastic anemia in a patient with persistent human parvovirus B19 infection.
- Haemolytic anaemia after lung transplantation: an immune-mediated phenomenon?
- High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood.
- Effect of maternal anti-HPA-1a antibodies and polyclonal IVIG on the activation status of vascular endothelial cells.
- Successful treatment of severe aplastic anemia associated with human parvovirus B19 and Epstein-Barr virus in a healthy subject with allo-BMT.
- Thrombotic complications after intravenous immunoglobulin therapy in two patients.
- Clinical experience with Octagam, a solvent detergent (SD) virus inactivated intravenous gammaglobulin.
- HLA antibodies and neonatal alloimmune thrombocytopenia.
- Congenital aplastic anemia caused by parvovirus B19 infection
- Durable response to combination therapy including staphylococcal protein A immunoadsorption in life-threatening refractory autoimmune hemolysis.
- Difficulties in the management of an incomplete form of refractory thrombotic thrombocytopenic purpura, the usefulness of vincristine.
- Experiences with fetomaternal alloimmune thrombocytopenia at a Swedish hospital over a 10-year period.
- Remission of severe, intractable autoimmune haemolytic anaemia following matched unrelated donor transplantation.
- Intravenous immunoglobulin G and anti-D as therapeutic interventions in immune thrombocytopenic purpura.
- [Fetal-neonatal alloimmune thrombocytopenia]
- Acute disseminated encephalomyelitis in autoimmune hemolytic anemia.
- The use of intravenous gamma-globulin in idiopathic thrombocytopenic purpura.
- Successful treatment of thrombocytopenia and hemolytic anemia with IvIG in a patient with lupus-like syndrome after mismatched related PBSCT.
- Two-step immunoablative treatment with autologous peripheral blood CD34(+) cell transplantation in an 8-year-old boy with autoimmune haemolytic anaemia.
- Efficacy of low dose intravenous immunoglobulins for post-splenectomy treatment of autoimmune haemolytic anaemia in a patient with hereditary spherocytosis.
- Autoimmune cytopenias associated with malignancies and successfully treated with intravenous immune globulins: about two cases.
- Treatment of hematologic disorders other than immune thrombocytopenic purpura with intravenous immunoglobulin (IVIg) - report of seven cases and review of the literature.
- Fatal autoimmune hemolytic anemia in a child due to warm-reactive immunoglobulin M antibody.
- Human intravenous immunoglobulin therapy.
- Successful control of refractory and life-threatening autoimmune hemolytic anemia with intravenous immunoglobulins in a man with the primary antiphospholipid syndrome.
- Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients.
- Infectious Diseases
- Intravenous immunoglobulin for severe infections: a survey of Canadian specialists.
- [High-dose immunoglobulin--life-saving in invasive group A streptococcal infection. Report of eleven cases with only one fatality]
- Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome.
- Group B streptococcal necrotizing fasciitis and toxic shock-like syndrome: a case report and review of the literature.
- Intravenous immunoglobulin adjunctive therapy in sepsis, with special emphasis on severe invasive group A streptococcal infections.
- Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial.
- Immunoglobulin therapy in non-menstrual streptococcal toxic shock syndrome.
- Streptococcal fasciitis with toxic shock syndrome in the pediatric patient.
- Intravenous immunoglobulin for prophylaxis and therapy of sepsis.
- Use of intravenous immunoglobulin in the treatment of staphylococcal and streptococcal toxic shock syndromes and related illnesses.
- Streptococcal toxic shock syndrome revealed by a peritonitis. Case report and review of the literature.
- Severe group A streptococcal infection and streptococcal toxic shock syndrome.
- The use of polyclonal intravenous immunoglobulins in the prevention and treatment of infectious diseases.
- Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group.
- Necrotizing fasciitis after peritonsillar abscess in an immunocompetent patient.
- Internal Medicine
- Neonatology
- Nephrology
- Neurology
- Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS).
- [Administration of intravenous immunoglobulins in neurology : An evidence-based consensus: update 2010.]
- [A case of anaphylactoid shock occurring immediately after the initiation of second intravenous administration of high-dose immunoglobulin (IVIg) in a patient with Crow-Fukase syndrome]
- Emerging drugs for Guillain-Barre syndrome.
- Severe steroid-resistant post-infectious encephalomyelitis: General features and effects of IVIg.
- Comparative analysis of therapeutic options used for myasthenia gravis.
- Immunotherapy of idiopathic inflammatory neuropathies.
- Plasma exchange after initial intravenous immunoglobulin treatment in guillain-barré syndrome: critical reassessment of effectiveness and cost-efficiency.
- Effectiveness of intravenous immunoglobulin treatment in adult patients with steroid-resistant monophasic or recurrent acute disseminated encephalomyelitis.
- Treatment strategies for myasthenia gravis.
- Surviving stiff-person syndrome: a case report.
- European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripher
- Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy.
- Adult-onset Still's Disease with Pulmonary and Cardiac Involvement and Response to Intravenous Immunoglobulin.
- Juvenile myasthenia gravis.
- Chronic inflammatory demyelinating polyneuropathy associated with tumor necrosis factor-alpha antagonists.
- [Current use of immunoglobulins in neurology :]
- [A case of Crow-Fukase syndrome with extramedullary plasmacytoma: marked clinical deterioration following a biopsy to plasmacytoma]
- Intravenous Immunoglobulin Treatment in Multifocal Motor Neuropathy.
- Crow-Fukase syndrome.
- High-dose intravenous immune globulin for stiff-person syndrome.
- High-dose intravenous immunoglobulin for the treatment of MuSK antibody-positive seronegative myasthenia gravis.
- Prominent plasmacytosis following intravenous immunoglobulin correlates with clinical improvement in Guillain-Barré syndrome.
- Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins.
- Stiff-person syndrome.
- [High-dose intravenous immunoglobulins for treatment of optic neuritis in Guillain-Barré syndrome]
- Switching to home-based SCIg for Multifocal motor neuropathy (MMN).
- [High doses of immunoglobulin G in the therapy for severe forms of myasthenia gravis and Guillain-Barre syndrome]
- Intravenous immunoglobulin therapy in POEMS syndrome: a case report.
- A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy.
- Nerve excitability changes after intravenous immunoglobulin infusions in multifocal motor neuropathy and chronic inflammatory demyelinating neuropathy.
- Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: the ICE trial.
- Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies.
- Motor recovery after Guillain-Barré syndrome in childhood.
- Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial.
- Pharmacoeconomics of therapy for Guillain-Barre syndrome: plasma exchange and intravenous immunoglobulin.
- Management of myasthenia gravis.
- What's new in multifocal motor neuropathy in 2007-2008?
- Current treatments of chronic immune-mediated demyelinating polyneuropathies.
- Guidelines on the use of intravenous immune globulin for neurologic conditions.
- Diagnosis and treatment of multifocal motor neuropathy.
- What's new in chronic inflammatory demyelinating polyradiculoneuropathy in 2007-2008?
- [Myasthenia gravis, pregnancy and delivery: a series of ten cases]
- Treatment of autoimmune myasthenia gravis.
- Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders.
- Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patients.
- Multifocal motor neuropathy: the diagnostic spectrum and response to treatment.
- Myasthenia gravis and myasthenic syndrome.
- Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial.
- Drug Insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues.
- [Actual aspects of myasthenia gravis treatment]
- [Multifocal motor neuropathies with conduction block: long-term follow-up of ten patients treated with IVIg]
- Guillain-Barre syndrome.
- Subcutaneous immunoglobulin infusion: A new therapeutic option in chronic inflammatory demyelinating polyneuropathy.
- Long-term effects of intravenous immunoglobulin in CIDP.
- European Federation of Neurological Societies/Peripheral Nerve Society Guideline* on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society.
- Intravenous immunoglobulin in the preparation of thymectomy for myasthenia gravis.
- [Treatment options for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)]
- Treatment of inflammatory and paraproteinemic neuropathies.
- Treatment for Lambert-Eaton myasthenic syndrome.
- Current therapeutic options in severe guillain-barre syndrome.
- Intravenous immunoglobulin for myasthenia gravis.
- Multifocal motor neuropathy presenting as chronic progressive proximal leg weakness.
- How long is IVIg effective in multifocal motor neuropathy?
- Intravenous immunoglobulin monotherapy in long-term treatment of myasthenia gravis.
- Guillain-Barre syndrome in the elderly: clinical, electrophysiological, therapeutic and outcome features.
- Multifocal motor neuropathy with conduction block: current issues in diagnosis and treatment.
- Posttransplant guillain barre syndrome
- Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis.
- High-dose intravenous immunoglobulin G treatment of myasthenia gravis.
- Treatment of multifocal motor neuropathy.
- Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis.
- Anterior interosseous nerve and multifocal motor neuropathy.
- [Present treatment of Guillain-Barre syndrome]
- [A comparative study of intravenous immunoglobulin and plasmapheresis preoperatively in myasthenia]
- Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment.
- Diagnosis and management of immune-mediated neuropathies
- Immunoadsorption in Guillain-Barre syndrome and myasthenia gravis.
- Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block.
- [Contribution of intravenous immunoglobulins to the treatment of myasthenia]
- [Use of IV immunoglobulins in neurology. Evidence-based consensus]
- Monofocal motor neuropathy: Improvement with intravenous immunoglobulin.
- [Modulation of experimental myasthenia gravis by IVIg]
- Disease severity in multifocal motor neuropathy and its association with the response to immunoglobulin treatment.
- Immunoglobulin improves a model of acute motor axonal neuropathy by preventing axonal degeneration.
- Axonal multifocal motor neuropathy without conduction block or other features of demyelination.
- Immunoglobulin treatment in refractory Myasthenia gravis
- High-dose intravenous immunoglobulin therapy in juvenile myasthenia gravis.
- Guillain-Barre syndrome: epidemiology, pathophysiology and management.
- [Multifocal motor neuropathy. Immediate response to intravenous immunoglobulin]
- Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies.
- Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study.
- Ten-year prospective study (clinical spectrum) of childhood Guillain-Barré syndrome in the Arabian peninsula: comparison of outcome in patients in the pre- and post-intravenous immunoglobulin eras.
- Serum tumour necrosis factor-alpha and soluble tumour necrosis factor receptors levels in patients with Guillain-Barre syndrome.
- A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome.
- Circulating tumour necrosis factor alpha & soluble TNF receptors in patients with Guillain-Barre syndrome.
- High-dose immunoglobulin therapy for Guillain-Barré syndrome in Japanese children.
- Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology.
- Guillain-Barré syndrome in a case of acute lymphoblastic leukaemia. A case report.
- Intravenous immunoglobulins in severe Guillian-Barre syndrome in childhood.
- High-dose intravenous immunoglobulin therapy in a child case of Bickerstaff's brainstem encephalitis
- Safety from thromboembolism using intravenous immunoglobulin therapy in Kawasaki disease: Study of whole-blood viscosity.
- [Acute Guillain-Barré-like polyradiculoneuritis revealing acute systemic lupus erythematosus: two case studies and review of the literature]
- Guillain-Barre syndrome and its frontiers
- Obstetrics
- Pediatrics
- Predictors of chronic idiopathic thrombocytopenic purpura.
- Kawasaki disease in adult patients.
- Immunological and clinical features of pediatric patients with primary hypogammaglobulinemia in Taiwan.
- Intravenous immune globulin versus intravenous anti-D immune globulin for the treatment of acute immune thrombocytopenic purpura.
- Intravenous immunoglobulin therapy leading to dramatic improvement in a patient with systemic juvenile idiopathic arthritis and severe pericarditis resistant to steroid pulse therapy.
- Idiopathic thrombocytopenic purpura in childhood: controversies and solutions.
- Kawasaki disease: clinical spectrum of 88 patients in a high-prevalence African-American population.
- Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study.
- [Effects of three intravenous gamma globulin regimens on Kawasaki disease and relevant coronary complication rates in pediatric patients: a comparative study]
- A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group.
- Kawasaki Disease.
- A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease.
- Kawasaki disease with severe cardiac sequelae: Lessons from recent New Zealand experience.
- Review and analysis of 283 cases of Kawasaki disease
- Coronary risk factors in Kawasaki disease treated with additional gammaglobulin.
- An immunoglobulin agent (IVIG) inhibits NF-kappaB activation in cultured endothelial cells of coronary arteries in vitro.
- Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan.
- An unusual pattern of arthritis in a child with Kawasaki syndrome.
- Epidemiologic study of Kawasaki disease at a single hospital in Daejeon, Korea (1987 through 2000).
- A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease.
- A national survey on the pediatric cardiologist's clinical approach for patients with Kawasaki disease.
- Labeled WBC cardiac imaging and two-dimensional echocardiography to evaluate high-dose gamma globulin treatment in Kawasaki disease.
- Fulminant myocarditis successfully treated with high-dose immunoglobulin.
- Efficacy of intravenous immune globulin therapy combined with dexamethasone for the initial treatment of acute Kawasaki disease
- Update on the treatment of Kawasaki disease in childhood.
- Pulmonology
- Rheumatology
- Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion.
- Efficacy of intravenous immunoglobulin treatment in lupus erythematosus chorea.
- A case report of the efficacy of apheresis for refractory autoimmune thrombocytopenia in a patient w
- Adult onset Still's disease and collapsing glomerulopathy: successful treatment with intravenous immunoglobulins and mycophenolate mofetil.
- Miscellaneous
- Experience with immunomodulatory treatments in Rasmussen's encephalitis.
- Rasmussen's syndrome.
- Dystonia, athetosis, and epilepsia partialis continua in a patient with late-onset Rasmussen's encephalitis.
- Positive response to immunomodulatory therapy in an adult patient with Rasmussen's encephalitis.
- Improvement in adult-onset Rasmussen's encephalitis with long-term immunomodulatory therapy.
- Medical treatment of Rasmussen's syndrome (chronic encephalitis and epilepsy): effect of high-dose steroids or immunoglobulins in 19 patients.
- PI
- Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies.
- Update on the treatment of primary immunodeficiencies.
- Immunoglobulin treatment in primary antibody deficiency.
- Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies.
- Immunodeficiencies.
- [The ESID Online Database for Primary Immunodeficiencies. First Analyses with Regard to Germany and Europe.]
- Alzheimer's
- Alpha-1 Antitrypsin
- Alpha-1 Antitrypsin
- Alpha-1 Antitrypsin Augmentation Therapy
- Airway Disease
- Guidelines
- Clotting Factors
- Hemophilia A
- Hemophilia B
- Von Willebrand Disease
- Prophylaxis Therapy
- Media and Information
- Press Releases
- PPTA Names Amy Efantis President & CEO
- PPTA Recognizes Essential Contributions of Plasma Donors
- GLOBAL INITIATIVE DRAWS ATTENTION TO RARE DISEASE TREATMENTS
- Rep. Matsui Recognizes International Plasma Awareness Week
- International Plasma Awareness Week: Plasma Donors are the Foundation
- David Bell Elected Chair of PPTA Global Board of Directors
- Patient Organizations and Industry Join Together to Celebrate Third Annual International Plasma Awareness Week
- Congresswoman Doris Matsui Recognizes International Plasma Awareness Week
- PPTA Celebrates International Plasma Awareness Week
- Alabama Lowers Minimum Donation Age to 18
- PPTA Recognizes World Hemophilia Day–April 17, 2015
- PPTA Recognizes 8th Annual International Rare Disease Day
- PPTA Introduces New Cross Donation Check System
- Ensuring Access to Medicines for Patients: Pharmaceutical Industry Associations Release ‘Principles for Communication of Information on Quality and Manufacturing Potential Supply Disruption’
- International Plasma Awareness Week to Celebrate Donors and Spotlight Rare Diseases
- PPTA Recognizes World Hemophilia Day 2014
- PPTA Recognizes First Plasma Collection Centers Certified in Hungary
- PPTA Letter to Stakeholders re: European Data Program Update
- PPTA Letter to Stakeholders re: European Data Program
- Plasma Protein Therapeutics Industry to Convene in Denver
- Patient Organizations Join Forces with Industry
- Industry, Donors and Patients to Convene in Vienna
- Plasma Donors and Rare Diseases Take Center Stage
- Inaugural Global Awareness Event Shines Spotlight on Plasma Donors and Rare Diseases
- PPTA Staff Honored with the Distinguished Alumni Award
- PPTA Applauds Preserving Access to Orphan Drugs Acts
- Discoveries and Developments: Highlights of the Plasma Protein Forum (June 2013)
- PPTA and Member Companies Demonstrate Sustained Commitment to Patient Safety (June 26, 2013)
- PPTA and Six Organizations Oppose NJ Tax on Clotting Factor (June 27, 2013)
- PPTA Recognizes World Hemophilia Day
- PPTA Statement: Effects of Sequester on Plasma Protein Therapies
- PPTA Recognizes International Rare Disease Day 2013
- Kedrion CEO Assumes Board Helm of PPTA
- PPTA applauds the House of Representatives for Passing Milestone IVIG Access Act
- Plasma Collection Continues to Gain Traction in Czech Republic
- PPTA Presents at the European Haemophilia Consortium
- PPTA Presents at ESID 2012
- PPTA's 2012 Plasma Protein Forum
- Celebrating PPTA's 20th Anniversary
- First Internationally Certified Plasma Collection Center in Czech Republic
- In Memoriam of Dr. Otto Schwarz
- PPTA Honored in House of Representatives
- PPTA Comments to FDA
- PPTA Recognizes World Hemophilia Day
- PPTA Recognizes International Rare Disease Day 2012
- PPTA Letter to Stakeholders re: North America Data Program
- PPTA Letter to Stakeholders re: North America Data Program
- California State Assemblymember Atkins Honored At PPTA's Business Forum
- PPTA Attends FDA Public Workshop on Drug Shortages
- Californians And Floridians Recognized For Role In Helping Rare Disease Patients Who Need Lifesaving Therapies
- ConQuaestor Report Confirms Cross Subsidies Within Sanquin
- IRS Proposed Regulations on Orphan Drug Exclusion from Drug Tax Stand to Harm Future Development of Treatments for Rare Disease Patients
- PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies
- PPTA Praises Legislation that Protects the Treatment of Rare Diseases
- PPTA Opposes Tax on Blood Clotting Factor
- PPTA Industry Expert Invited To Serve On HHS Advisory Committee On Blood Safety And Availability
- PPTA Hosts Discussion Forum on Blood/Plasma Products in The Hague
- PPTA Applauds the Florida Legislature for Preserving Medicaid Patient Access to Blood Clotting Factor
- PPTA Commends Congress and President Obama for Repealing the 1099 Tax-reporting Provision
- New Spanish Language Translations Available on PPTA Websites
- PPTA Hosts Congressional Staff Briefing
- PPTA Statement: Proven Safety of Human Albumin
- Patient Organizations and Industry Join Together to Celebrate Fourth Annual International Plasma Awareness Week
- Statements
- PPTA Statements
- PPTA Responds to New York Times Article
- PPTA Comments on Time Magazine Article
- Statement on Romanian Competition Council
- Joint pharmaceutical industry statement on the Commission’s proposal for a Regulation on health technology assessment (HTA)
- PPTA Statement on “How Blood-Plasma Companies Target the Poorest Americans”
- Plasma protein product safety and Creutzfeldt-Jakob disease (CJD)
- Statement from Jan M. Bult, President & CEO, Plasma Protein Therapeutics Association
- PPTA is Proud to Support Rare Disease Day 2017
- PPTA Statement on the Documentary “Das Geschäft mit dem Blut”
- PPTA Recognizes World PI Week: April 22-29, 2016
- PPTA Recognizes World Hemophilia Day–April 17, 2016
- FDA Releases Final Guidance on MSM Deferral Policy
- PPTA Letter to Stakeholders re: North America Data Program
- PPTA Letter to Stakeholders re: European Data Program Update
- PPTA Statement on Review of Donor Blood Pressure Requirements
- PPTA Statement on Review of Donor Weight Loss Monitoring
- PPTA Statement on Management of Donors and Units that Test Positive for Hepatitis B Virus (HBV) DNA by Nucleic Acid Tests (NAT)
- PPTA Statement on Current Considerations on Plasma Obtained from Whole Blood Donors for Further Manufacturing Use
- Statement on Update on Safety of Albumin
- PPTA Stat ement on the Rare Bleeding Disorders Workshop
- PPTA Statement on Clinical and Surrogate Endpoints for Evaluating Efficacy of Alpha 1-Proteinase Inhibitor (Human) Augmentation Therapy
- Dengue Virus and Plasma Protein Therapies
- Human Parvovirus PARV4 and plasma protein therapies
- Citrate Anticoagulant and Apheresis Perspective of Plasma Protein Therapeutics Industry
- PPTA Statement on Safety of Plasma Protein Therapies and the H5N1 Virus es
- Statement on the Safety of Plasma Protein Therapies and Swine Influenza Virus
- PPTA Statement on MSM Donor Policy
- PPTA Statement: Effects of Sequester on Plasma Protein Therapies
- PPTA Statement: Proven Safety of Human Albumin
- PPTA Comments on the IQWiG Rapid Report on Haemophilia Therapies
- PPTA Statement on Signing of Health Care Reform Bill
- Ebola Virus and Plasma Protein Therapies
- PPTA's Updated Response to Ontario's Proposal to Ban Compensated Plasma Donation
- Zika Virus and Plasma Protein Therapies
- Access to Care
- News
- PPTA News
- PPTA Highlights Importance of Patient Access to Plasma Protein Therapies
- Donor ethics letter submitted to the Expert Panel on Immune Globulin Product Supply and Related Impacts in Canada
- PPTA Responds to The Pharmaceutical Journal
- PPTA is concerned that the U.S. Senate is considering legislation that would move control over essential health benefits to all 50 states
- The U.S. Senate will try to move forward shortly on a “motion to proceed” to debate on repeal of the Affordable Care Act
- Endangering Patient's Access to Care: Proposals to Repeal the Affordable Care Act
- 2018 Plasma Protein Forum Highlights
- PPTA Presents in Malta
- PPTA Proudly Supports World Hemophilia Day 2017
- The Hilfenhaus Award conferred to Prof. Farkas at the IPPC 2017
- PPTA Remembers John W. Walsh
- PPTA Remembers Corey Dubin
- PPTA Supports 9th Annual International Rare Disease Day
- Vale - Guelfo Marcucci – Father of Italian fractionation
- New Study Shows Increased Development of Inhibitors using Recombinant Factor VIII
- New Supplement Addresses Hemolytic Complications of IVIG Infusions
- PPTA Mourns Passing of Dr. Víctor Grífols Lucas
- Initiation of the Five Week Enrollment Period for the Medicare IVIG Demonstration Project
- EHC Video on European Recommendations for Haemophilia Treatment
- Restrictive Coverage Policies and Patient Access
- Vaccine Recommendations for Patients with PI
- PPTA Announcement: DLA Piper to Provide Federal Legislative Representation
- PPTA's Response to Ontario's Proposal to Ban Compensated Plasma Donation
- IN MEMORIAM: MENSO BULT
- Rare Disease Day Congressional Tele-Town Hall
- IN MEMORIAM THEO EVERS
- PPTA Recognizes International Rare Disease Day 2014
- PPTA Strengthens Global Brand
- FDA Request to Cease Blood Collection in Florida
- Ethical Considerations in Compensated Plasma Donation
- PPTA Chosen to Join Mission to China
- Source Plasma News
- Regulatory Policy News
- Public Workshop Focuses on Immune Globulin Products
- FDA Posts Public Meeting Documents
- 115th meeting of the FDA Blood Products Advisory Committee
- PPTA Presents at ACBTSA Meeting
- PPTA Attends the 114th Meeting of the FDA Blood Products Advisory Committee (BPAC)
- BPAC Meets to Hear Research Program Updates
- PPTA Co-Sponsors Public Workshop
- PPTA Staff Honored with the Distinguished Alumni Award
- FDA Launches New Quality/Compliance Web Content
- PPTA Participates in Health Canada Roundtable
- FDA Announces Meeting Date: Blood Products Advisory Committee
- Meetings and Events News
- Patient Access News
- Global Access News
- Free Trade News
- PlasmaLit Database Updates
Plasma Products Databases
Media and Information
Copyright © 2018 PPTA. All rights reserved. (202) 789-3100